Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

71.58USD
24 Apr 2015
Change (% chg)

$-0.82 (-1.13%)
Prev Close
$72.40
Open
$72.22
Day's High
$72.37
Day's Low
$71.27
Volume
1,748,845
Avg. Vol
1,235,836
52-wk High
$77.46
52-wk Low
$57.37

LLY.N

Chart for LLY.N

About

Eli Lilly and Company discovers, develops, manufactures, and sells products in two business segments human pharmaceutical products and animal health products. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its animal health business, operating... (more)

Overall

Beta: 0.38
Market Cap(Mil.): $80,436.77
Shares Outstanding(Mil.): 1,111.01
Dividend: 0.50
Yield (%): 2.76

Financials

  LLY.N Industry Sector
P/E (TTM): 35.42 41.04 41.69
EPS (TTM): 2.04 -- --
ROI: -- 16.81 16.15
ROE: -- 17.31 16.96
Search Stocks

Lilly profit beats estimates, helped by cost cuts

- Eli Lilly and Co soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing, but revenue slipped as the stronger dollar hurt sales outside the United States.

23 Apr 2015

Lilly profit falls 27 percent, hurt by strong dollar

April 23 - Eli Lilly and Co reported a 27 percent fall in quarterly profit, hurt by a stronger dollar.

23 Apr 2015

Fitch Affirms Eli Lilly's IDR at 'A'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, April 21 (Fitch) Fitch Ratings affirms Eli Lilly & Co. Inc.'s (Lilly) long-term Issuer Default Rating (IDR) at 'A'. In addition, Fitch affirms the company's short-term IDR at 'F1'. The Rating Outlook is Stable. The rating actions apply to roughly $7.6 billion of debt outstanding at Dec. 31, 2014. A full list of the rating actions is provided at the end of this release. KEY RATING DRIVERS --Fitch views the acquisition of No

21 Apr 2015

Lilly's psoriatic arthritis drug succeeds in late-stage study

- Eli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients more than a placebo did in a late-stage trial.

20 Apr 2015

FDA recommends no changes to Lilly's schizophrenia injection use

- The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths.

23 Mar 2015

Court orders benefits for ex-Lilly manager with fibromyalgia

- A federal judge has ruled that a former manager at drug company Eli Lilly & Co is entitled to long-term disability benefits because she has fibromyalgia, overruling a determination by the company's disability plan.

18 Feb 2015

Drugmaker Lilly's Q4 profit falls on strong dollar, charge

Jan 30 - U.S. drugmaker Eli Lilly and Co reported a 41 percent fall in quarterly profit, hurt by a stronger dollar and a one-time charge related to a restructuring program.

30 Jan 2015

Lilly forecasts 2015 earnings, revenue shy of Street estimates

- Eli Lilly and Co forecast 2015 earnings and revenue just shy of market expectations as the drugmaker looks to bounce back after the expiration of patents on some of its biggest sellers.

07 Jan 2015

Lilly 2015 revenue forecast falls short of Wall St estimates

Jan 7 - Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 revenue shy of Wall Street expectations.

07 Jan 2015

BRIEF-Virbac closes Sentinel brands family acquisition Eli Lilly

* Announces closing of Sentinel brands family acquisition in United States from Eli Lilly

05 Jan 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks